Form 8-K - Current report:
SEC Accession No. 0001193125-24-271578
Filing Date
2024-12-05
Accepted
2024-12-05 16:32:31
Documents
19
Period of Report
2024-12-04
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d877731d8k.htm   iXBRL 8-K 33368
2 EX-1.1 d877731dex11.htm EX-1.1 235969
3 EX-4.1 d877731dex41.htm EX-4.1 73189
4 EX-5.1 d877731dex51.htm EX-5.1 14272
5 EX-99.1 d877731dex991.htm EX-99.1 9154
6 EX-99.2 d877731dex992.htm EX-99.2 9646
10 GRAPHIC g877731g01m94.jpg GRAPHIC 3355
  Complete submission text file 0001193125-24-271578.txt   606299

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA janx-20241204.xsd EX-101.SCH 2850
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE janx-20241204_lab.xml EX-101.LAB 18737
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE janx-20241204_pre.xml EX-101.PRE 11707
21 EXTRACTED XBRL INSTANCE DOCUMENT d877731d8k_htm.xml XML 3798
Mailing Address 10955 VISTA SORRENTO PARKWAY SUITE 200 SAN DIEGO CA 92130
Business Address 10955 VISTA SORRENTO PARKWAY SUITE 200 SAN DIEGO CA 92130 (858) 751-4493
Janux Therapeutics, Inc. (Filer) CIK: 0001817713 (see all company filings)

EIN.: 822289112 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40475 | Film No.: 241529537
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)